Overview

Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving a combination of injected interferon-alpha and oral ribavirin.
Phase:
Phase 2
Details
Lead Sponsor:
Amarillo Biosciences, Inc.
Collaborator:
CytoPharm, Inc.
Treatments:
Interferon alpha-2
Interferon-alfa-1b
Interferon-alpha
Interferons